Our Take
The FTC's divest-or-no-deal stance shows antitrust enforcement is teeth-first on hospital M&A, but Ascension signed off—meaning the deal likely survives, just smaller.
Why it matters
Health system consolidation continues to reshape outpatient surgery capacity and pricing. Practitioners in hospital operations and payers need to track which markets lose independent surgery centers and what that means for cost control.
Do this week
Payers and surgery center operators: map which of Ascension's seven divested centers serve your network before Q1 2025, so you can secure long-term capacity agreements before new owners take control.
FTC imposes divestiture as condition for Ascension-AmSurg deal
Ascension, a major health system undergoing financial turnaround, pursued the acquisition of AmSurg to consolidate outpatient surgical capacity. The FTC issued a consent order requiring Ascension to sell seven surgery centers as a condition of closing the deal (company-reported).
Ascension described the outcome as a compromise and indicated it was prepared to move forward with the divestitures. The $3.9 billion price tag reflects the scale of the transaction but does not account for the reduced footprint post-divestiture.
No timeline for completion of the seven sales was specified in available reporting.
Outpatient consolidation remains FTC priority
The FTC's willingness to condition approval rather than block outright suggests the regulator sees the deal as acceptable only at reduced scale. Divestiture as a remedy is standard antitrust practice, but its application here underscores sustained skepticism about hospital system roll-ups in outpatient settings, where pricing opacity and market concentration already raise concern among payers and employers.
For Ascension, the financial turnaround thesis depends partly on scale savings in back-office and procurement. Losing seven centers reduces that upside but does not kill the deal. For divested centers, the question shifts to who buys and on what terms. If smaller operators acquire them, competition may improve. If health systems in other regions scoop them, consolidation simply shifts geographically.
Payers and self-insured employers should track which markets lose centers and monitor pricing post-transaction.
Next steps for operators and payers
Health system executives: identify which seven centers are slated for sale and begin pre-marketing to potential buyers now. Delay invites buyer leverage on valuation.
Payers and benefits consultants: request the divested center list from Ascension and model surgery case migration. If your network loses a center, secure multi-year contracts with remaining or alternative providers before new ownership changes terms.
Surgery center owners and operators: monitor acquirer intent in your region. Ascension's forced sales may open bandwidth for independent or regional players to bid competitively.